Jun 6, 2017
HalioDx SAS, an immuno-oncology diagnostic company, presented Phase I data on LTX-315 at ASCO

Immunosign® gene signature assesses LTX-315 ability to turn ‘cold’ tumors ‘hot’ at ASCO 2017


Read HalioDX's press release